C2iTech is a biotechnology leader in respiratory therapeutics and organoid-based disease modelling. Our proprietary platforms integrate MSC-derived extracellular vesicles, immune-enhanced organoids, and automated lung injury models to accelerate drug discovery, repurposing, and preclinical validation.

Our technologies, backed by globally recognized experts in respiratory virology and pathogenesis and developed in collaboration with Hitachi, address complex conditions such as ARDS, COVID-19, and COPD.
Our innovations have earned multiple honours, including Gold and Silver Medals at the International Exhibition of Inventions Geneva, with Jury Commendations for breakthroughs in lung repair and personalised organoid systems.

We actively seeking collaboration with universities, pharmaceutical companies, biobanks, clinical facilities, and regional distributors to advance respiratory healthcare.

C2iTech Limited

Org chart

Teams

Offices